多发性骨髓瘤自体干细胞移植后的长期结局
该研究随访了1989至2018年间在美国阿肯色大学医学科学院接受自体干细胞移植(ASCT)的4329例新诊断多发性骨髓瘤(MM)患者,采用Kaplan-Meier分析、Cox比例风险模型、相对生存分析和治愈模型评估不同时期、风险组和人口学特征下的总生存(OS)和无进展生存(PFS)。结果显示OS稳步改善,2014年及以后治疗的患者相比1997年及以前治疗的患者OS更优(风险比0.35;95%CI 0.27-0.45),MM死亡的超额风险降低(相对超额风险0.30;95%CI 0.22-0.41)。治愈模型支持潜在治愈可能,范围在6.3%至31.3%之间,取决于治疗年份,多个时期有10.0%至18.6%的患者达到正常预期寿命。
要点
- ASCT后MM患者OS随治疗年代稳步改善
- 2014年后治疗者OS风险比0.35,超额死亡风险0.30
- 治愈模型显示潜在治愈率6.3%-31.3%
核心结论
- ASCT后MM患者长期OS稳步改善,治愈模型支持潜在治愈可能。
研究设计与样本
- 回顾性队列研究,纳入1989至2018年在美国阿肯色大学医学科学院接受ASCT的4329例新诊断MM患者。
- 采用Kaplan-Meier分析、Cox比例风险模型、相对生存分析和治愈模型评估OS和PFS。
主要发现
- 2014年及以后治疗的患者相比1997年及以前治疗的患者OS更优(风险比0.35;95%CI 0.27-0.45)。
- 2014年及以后治疗的患者MM死亡超额风险降低(相对超额风险0.30;95%CI 0.22-0.41)。
- 治愈模型显示潜在治愈率范围为6.3%至31.3%,取决于治疗年份。
- 多个时期有10.0%至18.6%的患者达到正常预期寿命。
- 有证据显示诊断后3年内早期死亡减少、完全缓解(CR)持续时间延长和CR后复发减少。
临床怎么用
- 长期随访数据支持ASCT在MM治疗中的持续应用和疗效改善。
- 治愈模型结果提示部分患者可能达到功能性治愈,需结合年龄、风险组和细胞遗传学特征个体化评估。
局限性
- 结果因年龄、风险组和细胞遗传学特征而异。
- 中间时期患者的OS、PFS和里程碑分析趋势不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As multiple myeloma (MM) treatments evolve, frequent updates are required to monitor the long-term effect of changes in approach. Traditionally, MM is considered an incurable disease, with most patients eventually relapsing. However, improvements in treatments has raised the possibility that MM might be functionally curable. To examine improvements in long-term survival, we followed 4329 patients with newly diagnosed MM treated with autologous stem cell transplantation (ASCT) at the University of Arkansas for Medical Sciences from 1989 through 2018. Overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan-Meier analysis, Cox proportional hazards models, relative survival analysis, and cure modeling among different time periods, risk groups, and demographic traits. Steady improvements in OS were found, with patients treated in 2014 or later having superior OS (hazard ratio, 0.35; 95% confidence interval [CI], 0.27-0.45) and reduced excess risk for MM death (relative excess risk, 0.30; 95% CI, 0.22-0.41) compared with patients treated in 1997 or earlier. Patients treated during intervening time periods often had intermediate survival, but trends in OS, PFS, and landmarked analyses were inconsistent. Cure models support the potential for cure, ranging from 6.3% to 31.3%, depending on the year of treatment, with 10.0% to 18.6% of patients achieving their normal life expectancy across multiple periods. There was some evidence of reductions in early mortality within 3 years of diagnosis, longer complete response (CR) duration, and reductions in relapse after achieving CR. However, results differed depending on age, risk group, and cytogenetic characteristics.
引用
- Nishimura KK, Barlogie B, van Rhee F, et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020. PMID: 31990333. doi:10.1182/bloodadvances.2019000524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。